MedTrace Logo

Nepafenac Compared to Placebo for Ocular Pain and Inflammation

NCT01426854 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2013-05-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to demonstrate that Nepafenac Ophthalmic Suspension, 0.1% is superior to Nepafenac Vehicle (placebo) for the prevention and treatment of ocular inflammation and pain associated with cataract surgery in Chinese subjects.

Conditions

  • Cataract

Interventions

DRUG

Nepafenac Ophthalmic Suspension, 0.1%

Topical ocular administration

OTHER

Nepafenac Vehicle Ophthalmic Solution

Inactive ingredients used as placebo; topical ocular administration

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Mandy Ye, Director · Alcon (China) Ophthalmic Product Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01426854 on ClinicalTrials.gov